SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market. It also designs, manufactures, and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Duluth, GA.

Boxlight Corporation - Ordinary Shares - Class A

Boxlight Corp

BOXL is trending due to a reported breakout potentially fueled by news of shipping Google EDLA-certified interactive displays. Community discussions revolve around short squeeze potential and high volatility. Some traders point to the company's history of dilution as a reason for caution, while others express optimism for a continued run.

AgriFORCE Growing Systems Ltd. is an agriculture technology company, which engages in the development and utilization of intellectual property (IP) assets for improvement. Its solutions include consulting, air and surface sterilization, and other projects. The company was founded on December 22, 2017 and is headquartered in Vancouver, Canada.

AgriFORCE Growing Systems ltd

AgriFORCE is trending due to news of a potential $550 million fundraising plan led by Anthony Scaramucci to acquire AVAX tokens, with the company potentially shifting its focus to crypto. The community is discussing the low float, potential for a squeeze, and comparing it to other recent runners. Some traders are also noting the company's planned name change to AVAX One.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to a Wedbush price target increase, driven by confidence in its nuclear growth strategy amid the AI revolution and potential policy tailwinds. Community members are debating the valuation, short interest, and the sustainability of the recent parabolic move, with some citing insider selling and potential dilution as concerns. The stock is also garnering attention as it broke ground on its first Aurora powerhouse in Idaho.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to its acquisition of Metsera, a company focused on obesity drugs, for up to $7.3 billion, a move that signals PFE's renewed interest in the weight-loss market. Community discussion revolves around the potential impact of this acquisition on competitors like Viking Therapeutics and the broader implications for Pfizer's pipeline and future growth strategy within the competitive pharmaceutical landscape.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

BINI is trending due to a planned reverse stock split, its ninth since 2022, leading to concerns about value dilution and potential delisting. The community expresses frustration and accuses the company of being a scam, with many sharing stories of significant losses and criticizing management. Discussions also include the broader context of reverse splits and regulatory oversight.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending as traders discuss the impact of the company receiving FDA 510(k) clearance for its RNA sequencing diagnostic device, Tempus xR IVD. Community members are highlighting the potential for a short squeeze and anticipating a climb to new all-time highs, with some suggesting a target price of $100. Bullish sentiment is fueled by the clearance's potential to support drug development programs and the company's growing presence in the AI-driven healthcare sector.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to news of Mike Alfred joining the board, sparking excitement about his potential to accelerate growth and shape the company's strategy in digital assets and AI. The community is actively discussing how this appointment could enhance Bakkt's position in the fintech and crypto space. Bullish sentiment is also fueled by speculation around potential acquisitions and the company's moves in the crypto sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid a critique amplified by Martin Shkreli questioning its technology's viability, sparking debate about its quantum advantage claims and long-term prospects. The community is weighing the criticism against positive developments like institutional buying and potential government support for quantum computing, resulting in volatile trading and discussions around short squeezes and future catalysts.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending due to discussions around a proposed merger with Strive, Inc. ($ASST) in an all-stock transaction that values SMLR at a significant premium, and community members are weighing the potential benefits and risks. Some traders are focusing on a lawsuit the company is facing, while others are eyeing the Bitcoin treasury aspect of the deal, especially as it relates to the valuation of both companies.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

MBX Biosciences is trending due to positive Phase 2 trial results for its hypoparathyroidism drug, canvuparatide, showing a significant responder rate and prompting discussions of potential Phase 3 advancement. The community is actively discussing the possibility of a short squeeze and the stock's potential to break past key resistance levels. This positive data and potential advancement come as the company is also working on an obesity candidate, contributing to overall investor excitement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure about $700 million of debt.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-refinancing-approximately-700">said</a> it will exchange approximately $700 million in aggregate principal amount of its existing convertible notes due 2027 for roughly $602 million in new 4.875% convertible senior notes due 2030, up to approximately 6.7 million shares of its common stock, and about $123.3 million in cash.Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to investors. A fear of a potential dilution appears to have disappointed investors. SRPT stock was down over 7% at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. The stock is among the top ten trending names on the platform.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_10_26_20_AM_png_8591ecfd20.webp" alt="Screenshot 2025-08-21 at 10.26.20 AM.png" width="569" height="62"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the refinancing.<stembedurl>https://stocktwits.com/scaredmoneymakenomoney/message/626069691</stembedurl>CEO Doug Ingram said that the exchange marks an important progress in the company’s long-term financial strategy. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position,” Ingram said.Ingram also said that the company believes it is well-positioned to fully fund its pipeline and meet its near-term obligations.Bank of America said that the debt refinancing transaction "makes sense" as it helps mitigate some near-term concerns about the company's ability to meet its obligations. Still, the firm continues to think clarity on uptake of Elevidys from here will be needed to get more comfortable with the long-term outlook.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals. Citi on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/citi-believes-fda-may-closely-watch-sarepta-safeguards-for-gene-therapy-in-non-ambulatory-dmd-patients/chsiUM2RdLP">said</a> that the U.S. Food and Drug Administration may take a “more comprehensive look” at the regimen devised by Sarepta for non-ambulatory patients.Last month, the company said that it had initiated immediate changes to reduce operating expenses, including a 36% workforce reduction and pipeline reprioritization, in a bid to meet its 2027 financial obligations.Following the crisis with the gene therapy, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">unwound</a> its equity position in Arrowhead Pharmaceuticals earlier this month, in less than a year of its investment.SRPT stock is down by 84% this year and by about 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-to-invest-2-billion-to-expand-manufacturing-in-north-carolina/chsSyKYRdig">This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Equity

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.


Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky...

H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its credibility in capital allocation.The firm also highlighted concerns that Sarepta's late-stage and commercial portfolio may not generate sufficient near-term cash to support its current debt and pipeline ambitions.H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. The brokerage noted that <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> fully unwound its equity position in Arrowhead less than a year after investing $325 million in the stock. The unwinding represented a 31% decline as compared to the purchase price, it added.On Stocktwits, retail sentiment around the stock trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Retail chatter around the stock jumped 131% over the past 24 hours, as of Thursday morning.<figure class="image"><img style="aspect-ratio:625/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_11_12_15_AM_png_aaca6c7ce4.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="625" height="58"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Sarepta selling its investment in Arrowhead.<stembedurl>https://stocktwits.com/Zergg/message/625149352</stembedurl>Another user hopes the stock will hit $30 by next week.<stembedurl>https://stocktwits.com/markxtill/message/625143002</stembedurl>Sarepta on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-keeps-retail-traders-bullish-as-stock-surges-on-100-m-milestone-payment-to-arrowhead-in-genetic-disorder-trial/chsR9ZARdak">said</a> that it sold about 9.27 million shares of common stock of Arrowhead in a privately negotiated block trade from which it expects to receive at least $174 million in gross proceeds.The company also said that it has entered into an agreement with Arrowhead under which it will transfer over 2.66 million shares of <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> back to the company to satisfy a $50 commitment of a $100 milestone payment obligation. The remaining $50 million will be received in cash, Arrowhead said. Sarepta previously owned 11.93 million shares of Arrowhead stock.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.However, SRPT stock is down by 84% this year and by 85% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hertz-expands-program-allowing-prolonged-3-day-test-drives-before-vehicle-purchase-to-over-100-cities/chsRlcNRdOh">Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review and enrollment progress in its Phase 1/2 trial of SRP-1003 for type 1 myotonic dystrophy (DM1) triggered a $100 million milestone payment to Arrowhead Pharmaceuticals.<a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> jumped 8.5% to close at $20.4 on Wednesday, with an additional 1.6% gain in after-hours trading.The payment was triggered after Arrowhead reached the first of two predetermined enrollment targets in the study, following a review of the safety data.&nbsp;SRP-1003 is an experimental RNA interference therapy being developed for type 1 myotonic dystrophy.To help fund the milestone payment, Sarepta sold 9.3 million shares of Arrowhead in a privately negotiated block trade, generating at least $174 million in gross proceeds.&nbsp;Arrowhead will also redeem 2.7 million shares from Sarepta for $50 million, prefunding half of the milestone obligation.The company plans to share early results from the SRP-1003 trial and its facioscapulohumeral muscular dystrophy (FSHD) program in the second half of 2025.On Stocktwits, retail sentiment was ‘bullish’ for Sarepta Therapeutics and ‘extremely bullish’ for Arrowhead Pharmaceuticals, with 24-hour message volumes surging 872% and 122%, respectively.One user remarked that upgrades for Sarepta Therapeutics keep coming, adding that the market may be underestimating how quickly sentiment can shift when major investors get involved.&nbsp;<stembedurl>https://stocktwits.com/BookerB/message/625098239</stembedurl>Another said the stock could still rise tenfold within a year if European approval comes through and with multiple trials underway, calling it a bargain and urging others to buy before the current discount disappears.<stembedurl>https://stocktwits.com/Mejeko/message/625096804</stembedurl>While Sarepta’s stock has declined 83.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/ARWR">Arrowhead’s stock</a> gained 6.3% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of Vinay Prasad at the U.S. Food and Drug Administration (FDA) highlighted what she described as political bias in the government’s vetting process, drawing a link to the termination of billionaire pilot Jared Isaacman’s nomination to lead NASA.In a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/LauraLoomer/status/1954672518146695299">post on X</a>, Loomer said Isaacman’s nomination was blocked “with malice” by staff, noting he is a registered Republican who donated more to Donald Trump than to Democrats and had “never publicly attacked Trump.”&nbsp;"Vinay Prasad is not only a Democrat donor, but he's also a Trump hater and he is a Marxist who said Trump is 'the worse person in the world,'" Loomer posted.&nbsp;"Isaacman is a registered Republican. And he's way more accomplished than the Marxist Trojan Horse at the US FDA," she added. "Just more evidence of a broken vetting system with no standards."Prasad, a former UCSF epidemiologist and vocal critic of certain vaccine policies, stepped down on July 30 as head of the FDA’s Center for Biologics Evaluation and Research (CBER) after&nbsp;serving in the role for approximately three months.&nbsp;His resignation followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">backlash over the agency’s handling of Sarepta Therapeutics’ Elevidys</a>, the only approved gene therapy for Duchenne muscular dystrophy. In July, Prasad and FDA Commissioner Marty Makary had asked Sarepta to pause shipments of Elevidys after three reported patient deaths, two of which were linked to liver failure.The move drew criticism from patient advocacy groups and conservative commentators, with The Wall Street Journal’s editorial board calling it a “mugging” that could deter future drug innovation. Conservative influencers, including Loomer, resurfaced Prasad’s past social media posts supporting progressive politicians and criticizing Trump.The FDA later reversed course, allowing Sarepta to resume shipments to children who can still walk, while maintaining a pause for non-ambulatory patients pending updated safety labeling. Prasad, who had questioned the therapy’s approval, described the treatment as one that “seems to be killing kids” in comments earlier this year.Prasad was appointed in May to replace Peter Marks, who was removed after policy disagreements with Health and Human Services Secretary Robert F. Kennedy Jr. During his tenure, Prasad sought to overhaul the FDA’s vaccine approach, including restricting COVID-19 vaccine approvals from Moderna and Novavax to high-risk groups only.Trump later ordered Prasad’s removal from CBER,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-overrode-rfk-jr-and-makary-to-remove-fda-biologics-chief-amid-sarepta-drug-controversy-report/chohDhVR5CH">overriding opposition</a> from Kennedy and Makary, according to Politico. Following his exit, Makary named George Tidmarsh as acting director.Meanwhile, Citi raised its price target on Sarepta Therapeutics (SRPT) to $14 from $12 while maintaining a ‘Sell’ rating, citing a second quarter (Q2) sales beat driven by a Roche milestone payment for Japanese Elevidys approval, gains on strategic investments and an income tax benefit, but warned the Elevidys liver-toxicity overhang remains a risk.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-gets-price-target-hike-from-wells-fargo/chrmBLTRd3a">Sarepta’s Q2 revenue</a> rose to $611.1 million from $531.04 million a year earlier, with EPS of $2.02 topping estimates, and the company reaffirmed it is on track for over $100 million in cost savings through 2025 under its July restructuring plan.On Stocktwits, retail sentiment for Sarepta was ‘bullish’ amid ‘low’ message volume.<a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> has declined&nbsp;by over 85% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Far-right activist Laura Loomer. (Photo credit: Getty Images)

Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman

Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced shipment restrictions following patient deaths before being partially reinstated.

Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s second-quarter earnings beat Wall Street expectations on Wednesday.Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. The analyst kept an ‘Overweight’ rating on the shares.The firm reiterated its confidence in the Elevidys franchise, noting that it sees an intact benefit-risk for ambulatory patients and potential upside from future updates on the non-ambulatory side.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> remained unmoved within ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_11_16_43_AM_png_bbc7e903bf.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the second-quarter sales number shows that the recent patient deaths did not undermine demand.<stembedurl>https://stocktwits.com/parbv/message/624138164</stembedurl>Another highlighted that Elevidys caters to a niche patient population not addressed by many others.<stembedurl>https://stocktwits.com/Bearcase/message/624132232</stembedurl>Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease primarily impacts boys.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals, CEO Doug Ingram said on Wednesday.For the second quarter, Sarepta reported total revenues of $611.1 million, above an analyst estimate of $531.04 million, owing to higher net product revenue of Elevidys. Adjusted and diluted earnings per share came in at $2.02, up from $0.43 in the corresponding quarter of 2024, and above an analyst estimate of $0.67.The company also said that it is on track to realize over $100 million in cost savings through the end of 2025 as part of the restructuring announced in July. SRPT stock is down by about 86% this year and by about 87% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/duolingo-stock-rockets-30-percent/chrm761Rd37">Duolingo Stock Rockets 30% And Retail Chatter Surges A Whopping 1,400% In 24 Hours: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity

Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. 

Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

U.S. stocks appear set for a positive opening on Thursday as President Donald Trump’s deadline for reciprocal tariffs kicked in from midnight Thursday.In a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/114985420201139599">post</a> on Truth Social, President Trump celebrated that billions of dollars are now flowing into the United States from countries that have “taken advantage” of the U.S. for many years.“The only thing that can stop America’s greatness would be a radical left court that wants to see our country fail!” President Trump said in the post.<figure class="image"><img style="aspect-ratio:594/247;" src="https://news.stocktwits-cdn.com/Trump_post_jpg_40c056c48a.webp" alt="President Donald Trump's post on Truth Social" width="594" height="247"><figcaption>President Donald Trump's post on Truth Social | @realDonaldTrump/Truth Social</figcaption></figure>While Dow Jones futures rose 0.61% at the time of writing, the S&amp;P 500 futures gained 0.7%, while the tech-heavy Nasdaq 100’s futures surged 0.8%. Futures of the Russell 2000 index were up 0.93%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) gained 0.7% at the time of writing, while&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) was up 0.8% on Thursday morning. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘neutral’ territory.Asian markets ended Thursday’s trading session on a positive note, with the TWSE Capitalization Weighted Stock index leading with gains of 2.32%, followed by the KOSPI at 0.92%, and the Nikkei 225 at 0.56%.The Hang Seng rose 0.35%, while the Shanghai Composite gained 0.16%.Stocks To Watch<ul><li>Apple Inc. (AAPL): Apple shares surged nearly 3% in Thursday’s pre-market session after the iPhone maker outlined its plans to invest an additional $100 billion in the U.S. Shares of precision-glass maker Corning Inc. (GLW) surged nearly 6% after Apple said it would expand its partnership with the company.</li><li>Nvidia Corp. (NVDA), Intel Corp. (INTC), Advanced Micro Devices Inc. (AMD): Shares of semiconductor companies gained between 1% and 2% after President Trump announced exemptions on nearly all semiconductor chip imports.</li><li>Eli Lilly &amp; Co. (LLY): Eli Lilly shares plummeted over 14% in the pre-market session. The company announced the outcome of a late-stage trial of its daily obesity pill on Thursday morning.</li><li>Sarepta Therapeutics Inc. (SRPT): Sarepta shares surged 12% after the company’s second-quarter (Q2) results beat Wall Street expectations. Sarepta reported earnings per share (EPS) of $2.02 on revenue of $611 million, compared to an estimated EPS of $0.83 on revenue of $531 million, according to Stocktwits data.</li><li>Twilio Inc. (TWLO), Block Inc. (XYZ), SoundHound AI Inc. (SOUN), and Rocket Lab USA Inc. (RKLB) are among the companies reporting their latest results on Thursday.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-lisa-su-positive-signals-good-indications-china-export-licenses/chrSP0nRd5S">AMD CEO Lisa Su Seeing A ‘Lot Of Positive Signals’ About Computing Needs, Says ‘Good Indications’ In Sight On China Export Licenses</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Rise As Trump’s Reciprocal Tariff Deadline Kicks In: AAPL, NVDA, INTC, LLY, SRPT Among Stocks To Watch

While Dow Jones futures rose 0.61% at the time of writing, the S&P 500 futures gained 0.7%.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPT Sarepta Therapeutics Inc